April 29, 2026 HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026 Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference